Incinerate, Track, Prove: Inside Indonesia’s high‑potency pharma waste crackdown

Only about 2.8% of Indonesian hospitals can destroy hazardous medical and pharmaceutical waste on site. Out of 2,889 hospitals nationwide, just ~82 have their own incineration or autoclaving capacity, which is why most B3 (hazardous/toxic) waste is transported off‑site for destruction (pulitzercenter.org).

Before COVID‑19, Indonesia was already incinerating roughly 290 tons of medical (including pharmaceutical) B3 waste daily—about 0.1 kg per inhabitant per day. The pandemic pushed volumes to around five times that, exposing gaps and spurring a buildout of permitted capacity (pulitzercenter.org).

Policy has kept pace. The Ministry of Environment and Forestry (MoEF) mandates electronic manifests (“Festronik”) with GPS tracking for every B3 shipment, and newer rules emphasize sorting and delivery only to designated facilities (enviliance.com).

Regulatory designation and prohibitions

High‑potency pharmaceutical wastes—anticancer cytotoxics and mutagenic drugs—are B3 under Indonesia’s Environmental Protection Law (Laws 32/2009), PP 101/2014, and MoEF regulations. MoEF Reg. 4/2020 requires the Festronik e‑manifest and GPS tracking, while MoEF Reg. 9/2024 underscores sorting, reduction, and delivery to designated facilities (enviliance.com). Hospitals must segregate expired meds, cytotoxic materials, and contaminated sharps into B3 streams, store pharmaceutical waste in nonreactive containers, and hand it to licensed B3 vendors with weighing and manifest protocols (keslan.kemkes.go.id).

Internationally, the direction is the same. U.S. EPA rules at 40 CFR 266 Subpart P treat many discarded drugs (P‑listed, U‑listed) as RCRA hazardous waste and explicitly prohibit sewering or landfilling. EPA publications recommend that “pharmaceutical waste [be] incinerated instead of being drain disposed or land‑filled,” and that facilities “set up a program to incinerate” such waste (nepis.epa.gov; nepis.epa.gov). WHO likewise notes that only modern incinerators at 850–1100 °C (with flue‑gas cleaning) adequately neutralize toxic healthcare waste, and that sewer disposal of drugs is forbidden (who.int).

Approved destruction technologies and limits

High‑temperature incineration is the principal approved method for treated high‑potency pharmaceutical waste. Modern units run at ≥850–1000 °C and use multi‑chamber designs with flue‑gas scrubbers to meet emission standards (e.g., dioxins, heavy metals) (nepis.epa.gov; who.int). Indonesia is expanding capacity: a new PPLI hazardous‑waste incinerator, permitted after trials, can destroy ~50 tons/day and is authorized to treat medical/pharmaceutical waste, using heat to “destroy pollutants… and significantly reduce the mass and volume” (ppli.co.id; ppli.co.id).

Hospital‑scale units are also used in some regions to handle local waste on site (e.g., the i8‑M700). Alternatives such as autoclaving, microwaving, or steam sterilization are suitable for infectious or non‑toxic medical waste, but generally cannot deactivate highly toxic drug residues; alkaline hydrolysis and steam digesters also cannot guarantee chemical decomposition of cytotoxics (who.int). Experimental pyrolysis/gasification shows promise: in one study, a combined pyrolysis–gasifier (“Pyropure”) achieved >99% destruction of 17 structurally diverse drugs with negligible active by‑products (pmc.ncbi.nlm.nih.gov). These systems are not yet widely approved; any residual matter must still be classified and often incinerated if hazardous.

Prohibitions and residues handling

Land disposal of pharmaceutical waste is forbidden under Indonesian B3 rules and international norms, and incinerator ash must go to engineered landfills that meet treatment standards. In the U.S., land‑disposal restrictions prescribe incineration as the treatment standard for most hazardous drugs (epa.gov). Indonesian guidance similarly requires ultimate destruction, not dilution; one hospital B3 manual states that “usually pharmaceutical waste must be disposed via incinerator” and that dumping into sewers is “not recommended” (id.scribd.com). A narrow exception appears in the same manual: very dilute urine/vomit from patients on chemotherapy may be discharged to sewage under controlled conditions—this refers to low‑concentration excreta, not intact drug products (id.scribd.com).

Emissions control and compliance

Uncontrolled burning of drug waste releases hazardous air pollutants; high‑efficiency incinerators with exhaust scrubbing are therefore mandated. WHO cautions that poorly managed incineration of chlorine‑bearing materials or mercury generates toxic emissions (who.int). Indonesia emphasizes compliance: the new PPLI incinerator was trial‑verified and permitted based on emission criteria, and “medical waste is one [waste stream] that can be managed with this method” (ppli.co.id; ppli.co.id). Large‑scale controlled incineration is far safer environmentally than open burning or dumping of cytotoxic drugs.

Waste characterization standards

Proper disposal starts with characterization: listing active pharmaceutical ingredients (API), consulting Safety Data Sheets (SDS), and assessing hazards. Formulations containing P‑listed or toxic U‑listed ingredients (e.g., many chemotherapy agents) are legally hazardous when discarded under RCRA (Resource Conservation and Recovery Act). Wastes must also be assessed for characteristics such as ignitability and toxicity; high‑alcohol injectables are ignitable, and drugs with heavy metallic preservatives (lead, mercury) can fail the TCLP (toxicity characteristic leaching procedure, a lab test simulating leachate) (nepis.epa.gov; who.int).

Hospitals often rely on vendor databases to classify each NDC (National Drug Code) product, but under “cradle‑to‑grave” rules the generator remains responsible (nepis.epa.gov). EPA guidance adds that if TCLP leachate meets or exceeds regulatory levels, the waste must be managed as hazardous; if uncertain, a conservative approach applies (nepis.epa.gov). By analogy, Indonesian B3 rules require treating potentially cytotoxic or toxic pharmaceutical waste as B3 unless proven otherwise.

Segregation, packaging, and storage

After classification, waste is segregated: high‑potency drug products, contaminated materials (gowns, syringes), and trace chemo waste (empty vials, gloves) go into designated cytotoxic bins; expired non‑hazardous pharmacy waste is kept separate. Containers must be clearly labeled with “B3” symbols and, for liquids, be non‑reactive and leak‑proof (id.scribd.com). Moist pharmaceutical liquids, such as antibiotic solutions and vaccines, should be absorbed (e.g., with sawdust) and bagged before final treatment (id.scribd.com).

Third‑party B3 firms typically incinerate the waste and return ash residue to registered collectors, closing the loop from generator to final residue management (keslan.kemkes.go.id).

Electronic manifests and chain of custody

Every B3 transfer requires documentation. Under MoEF Reg. 4/2020, transporters use the Festronik e‑manifest (initiated by the generator) and GPS tracking (enviliance.com). In practice, hospitals weigh and record waste in their temporary storage (TPS) and prepare a signed “surat jalan” with waste type, quantity, generator ID, and destination—often accompanied by a weight ticket or “bukti pengambilan limbah”—as proof of transfer (keslan.kemkes.go.id).

Manifests describe the waste and its constituents (per SDS), include classification codes (U.S. manifests may use “PHARMS”; Indonesia uses national B3 codes), and specify the disposal method (e.g., “to incinerator”). By regulation, treated pharmaceutical waste must go to an incinerator or other authorized destruction unit. Upon receipt, the facility records delivery, completes any treatment checks (e.g., verification of PCI and permit; PCI is a context‑specific verification step referenced by operators), and issues a certificate of destruction. Hospitals retain manifests and certificates, ensuring traceability and legal proof of safe destruction (keslan.kemkes.go.id; keslan.kemkes.go.id).

Capacity gaps and expansion

Because only ~82 of 2,889 hospitals (≈2.8%) have on‑site treatment, Indonesia relies on off‑site licensed facilities. Prior to COVID‑19, ~290 tons/day were incinerated nationwide; during the pandemic, volumes rose roughly fivefold, increasing the risk of illegal burning or dumping in areas without capacity (pulitzercenter.org). Expansion is underway through projects such as the permitted PPLI incinerator (~50 tons/day) and other initiatives (ppli.co.id).

Authorities say tracking is improving outcomes: an EPA‑supported 2024 “silacak” database indicates Festronik has raised compliance, with nearly 100% of large hospital B3 shipments now reaching licensed incinerators (enviliance.com; keslan.kemkes.go.id).

Outcomes and efficiency metrics

WHO‑aligned segregation plus incineration can nearly eliminate emissions of intact drugs, and EPA reporting notes that rigorous compliance (no dumping; all hazardous pharmaceuticals combusted) reduces pharmaceutical loads in waterways (who.int). In practical terms, incineration destroys >99% of active compounds in pharmaceutical waste, whereas landfilling or uncontrolled burning leaves residues that leach into soil or air. Proper coding and manifesting help facilities avoid fines and environmental damage, turning toxic wastes into inert ash with large volume reductions and pollutant destruction (ppli.co.id; nepis.epa.gov).

Global reviews concur: returning unused drugs to pharmacies for centralized high‑temperature incineration is “the safest” option from an environmental perspective (pmc.ncbi.nlm.nih.gov).

Citations and sources

Regulatory texts and guidelines (Indonesia’s PP 101/2014; MoEF 4/2020, 9/2024; Permenkes 66/2016) enforce the practices summarized above (enviliance.com; keslan.kemkes.go.id; id.scribd.com). Internationally, the EPA’s 2019 pharmaceutical rule and WHO’s health‑care waste guidance favor incineration and ban sewer/landfill of hazardous drugs (nepis.epa.gov; who.int). Empirical reports quantify capacity and destruction efficiency (EPA; PPLI; Bean et al., 2016) (ppli.co.id; pmc.ncbi.nlm.nih.gov).

Sources: U.S. EPA (2022) Ten‑Step Blueprint for Managing Pharmaceutical Waste in Healthcare Facilities (nepis.epa.gov; nepis.epa.gov); WHO (2018) Health‑care Waste fact sheet (who.int); MoEF Regs. (2020, 2024) summaries (enviliance.com); Indonesian Ministry of Health B3 guidance (keslan.kemkes.go.id; keslan.kemkes.go.id); Bean et al. (2016) Environ. Manage. (pyrolysis study) (pmc.ncbi.nlm.nih.gov); Pulitzer/Adi Renaldi (2020) (pulitzercenter.org); PPLI press release (2024) (ppli.co.id).